Progressive Supranuclear Palsy
Review articles bring together what experts know so far about one topic. They're a good next step if you want to go deeper than the monthly updates on progressive supranuclear palsy.
This list only includes reviews published in 2026, newest first. These publications are not summarized or checked here; each link goes to the original, which belongs to its authors and journal. Behind a paywall? Authors are often happy to email a copy if you ask them, and some public libraries can get articles for you. Everything on MedicalUpdates.ai is free.
How to read a review with an AI assistant
For articles marked "Read free full text", you can paste the article into an AI assistant (such as ChatGPT, Claude or Gemini) and ask it to explain it. This prompt asks it to show where each point comes from:
Summarize this review article for a patient with progressive supranuclear palsy, in plain language. For each main point, quote the sentence from the article it comes from. Keep what the authors found separate from what they suggest or believe. If the article does not say something, write "the article does not say" instead of guessing. End with three questions I could ask my care team.
AI assistants can leave things out or get them wrong, even with this prompt. Check anything important against the article itself. Do not paste your own medical details. This is for understanding, not for making treatment decisions: talk them through with your care team.
Most useful for patients and families (11)
From target engagement to translational disconnect: A systematic review and narrative synthesis of direct tau-targeted clinical trials in Alzheimer's disease and primary tauopathies.
Yin L, et al. Pharmacol Res, September 2026
Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists.
Anis S, et al. Mov Disord Clin Pract, September 2026
The eyes and Parkinsonian syndromes.
Chen BS, et al. Rev Neurol (Paris), September 2026
Rehabilitation strategies for atypical parkinsonian syndromes: A scoping review of progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, and dementia with Lewy bodies.
Kamo H, et al. J Parkinsons Dis, August 2026
Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication.
Leclercq V. J Neurol, June 2026
Cognitive and behavioral disturbances in PSP and MSA: clinical features and imaging correlates.
Ruiz-Barrio I, et al. J Neural Transm (Vienna), May 2026
A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.
Eijsvogel PPNM, et al. Clin Pharmacol Ther, May 2026
Exploring the phenotypic spectrum of frontotemporal lobar degeneration.
Patel J, et al. Neurol Neurochir Pol, April 2026
Dementia in Progressive Supranuclear Palsy: A Narrative Review.
Moore KS, et al. Neurol Ther, January 2026
Dysphagia and Dysarthria in Neurodegenerative Diseases: A Multisystem Network Approach to Assessment and Management.
Fiorella ML, et al. Audiol Res, January 2026
Voice and Speech in Atypical Parkinsonian Disorders.
Rodriguez-Porcel F, et al. Mov Disord Clin Pract, January 2026
More review articles (25)
Many of these go into more clinical or laboratory detail.
Advanced Eye Movement Features Measured by Quantitative Oculography as Candidate Biomarkers for Progressive Supranuclear Palsy.
Ouyang H, et al. Diagnostics (Basel), September 2026
Gut microbiome dysbiosis, short-chain fatty acid depletion and implications for neuroinflammation in atypical parkinsonian syndromes - a systematic review of patient cohorts.
Khan SA, et al. J Parkinsons Dis, September 2026
From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.
Harris GA, et al. Front Neurosci, August 2026
CD8+ T lymphocytes in progressive supranuclear palsy and corticobasal degeneration: Interactions with tau pathology and neuroinflammation.
Jasak P, et al. Parkinsonism Relat Disord, August 2026
Dramatic sex differences leading to different brain disease presentation: The requirement for sex-specific medications with ADNP/davunetide as a case study.
Lobyntseva A, et al. Front Neuroendocrinol, August 2026
Glymphatic dysfunction in cerebellar neurodegeneration: mechanistic insights and emerging clinical implications.
Rodriguez PF, et al. Neurol Sci, August 2026
Quantitative susceptibility mapping in neurodegenerative diseases: An umbrella review of iron-related biomarkers and mechanisms.
Ghaderi S, et al. Magn Reson Imaging, August 2026
Sleep-wake control with age and neurodegenerative diseases.
Tang WX, et al. Sleep Med Rev, August 2026
Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.
van de Zande NA, et al. Brain Commun, August 2026
From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.
Bernhardt AM, et al. Front Aging Neurosci, July 2026
Limb apraxia in Parkinson's disease and atypical parkinsonian syndromes: a systematic review.
Smaragdaki E, et al. Neurol Sci, July 2026
The role of SUMOylation in regulating proteins that drive neuronal disease progression.
Sidharth A, et al. Biochem Biophys Rep, July 2026
The Role of DaT-SPECT Imaging in the Evaluation of Progressive Supranuclear Palsy.
Giannakis A, et al. Life (Basel), June 2026
Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon.
Kovacs GG. Eur J Neurosci, June 2026
FDG-PET in Movement Disorders and Parkinsonian Syndromes.
Minoshima S, et al. PET Clin, June 2026
Conjecture for a free radical epimerization process in Alzheimer, Parkinson, Lewy body, amyotrophic lateral sclerosis, progressive Supranuclear Palsy and Creutzfeldt Jakob diseases.
Deloncle R. Exp Neurol, May 2026
Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.
Migda B, et al. Front Aging Neurosci, May 2026
The Possible Significance of Proteomics in Understanding Molecular Mechanisms of Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, and Dementia with Lewy Bodies.
Madetko-Alster N, et al. Cells, May 2026
Neuroprotection trial design in progressive supranuclear palsy: challenges and solutions.
Golbe LI, et al. Alzheimers Dement (N Y), April 2026
Elucidating the Neurobiological Underpinnings of Mild Behavioral Impairment in Tauopathies: Clinical and Molecular Insights.
Angelopoulou E, et al. Int J Mol Sci, April 2026
Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.
Dong C, et al. Transl Neurodegener, March 2026
Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism.
Angel Pinto MJ, et al. Curr Neurol Neurosci Rep, March 2026
Transcranial Sonography in the Examination of Atypical Parkinsonian Syndromes.
Alster P, et al. Biomedicines, March 2026
Current Neuroimaging Modalities to Distinguish Parkinson's Disease from its Mimics: Imaging Features and Implications for Clinical Practice.
Gad M, et al. Neuroradiol J, February 2026
Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.
Cilia R, et al. Brain Sci, January 2026
Reviews in other languages (3)
Articles not written in English. PubMed lists an English title, shown here.
[4-Repeat Tauopathies: Progressive Supranuclear Palsy and Corticobasal Degeneration].
Palleis CT, et al. Fortschr Neurol Psychiatr, September 2026
[Basal ganglia and movement disorders : Part 1: the parkinsonian spectrum-Neuroradiological patterns and diagnostic considerations].
Garner M. Radiologie (Heidelb), March 2026
[MRI in neurodegenerative Parkinsonian syndromes].
Schröter N, et al. Radiologie (Heidelb), February 2026